APGE

Business Context and Reporting Period

Company: Apogee Therapeutics, Inc. (Nasdaq: APGE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Apogee is a clinical-stage biotechnology company developing optimized, novel biologics for inflammatory and immunology (I&I) indications, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The company utilizes advanced antibody engineering to extend half-life, aiming for less frequent dosing compared to current standards of care.

Key Financial Metrics

Note: The company has no debt and no revenue. Liquidity is supported by cash and marketable securities totaling approximately $903 million as of December 31, 2025.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $73.7 million (40.5%) year-over-year, driven primarily by higher operating expenses.
• R&D Expense Growth: R&D expenses increased by $46.8 million. This was primarily due to increased clinical trial and manufacturing costs for the lead program, zumilokibart (APG777), and higher personnel-related costs. This increase was partially offset by decreases in expenses for APG990/APG279, APG333/APG273, and APG808 programs following milestone payments in 2024.
• G&A Expense Growth: G&A expenses increased by $21.9 million, largely due to increased headcount and higher equity-based compensation.
• Capital Raises: In October 2025, the company completed an underwritten public offering raising net proceeds of $324.1 million. Additionally, $67.6 million was raised via the At-The-Market (ATM) facility during 2025.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Liquidity: Management estimates that existing cash, cash equivalents, and marketable securities are sufficient to fund operating expenses and capital expenditure requirements into the second half of 2028.
• Clinical Milestones:
  • Zumilokibart (APG777): Positive 16-week data from the APEX Phase 2 Part A trial in AD was announced in July 2025. Part B enrollment was completed in January 2026, with topline data expected in Q2 2026. A Phase 3 trial in AD is planned for the second half of 2026, with a potential launch in 2029.
  • APG279: Phase 1b head-to-head trial against DUPIXENT in AD commenced in July 2025; data readout expected in H2 2026.
  • APG808: Positive interim results from Phase 1b in asthma announced in May 2025.

Risks and Contingencies

• Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional capital to advance clinical trials and commercialization.
• Third-Party Reliance: Apogee relies on third parties (e.g., WuXi Biologics, Samsung Biologics) for manufacturing and clinical trial execution. Disruptions in these supply chains, including potential impacts from the BIOSECURE Act or geopolitical tensions, pose significant risks.
• Regulatory Uncertainty: The company faces risks related to FDA and foreign regulatory approvals, including potential delays due to government shutdowns or changes in regulatory policy.
• Intellectual Property: The company relies on patents and licenses (including from Paragon) which may be challenged or expire before commercialization.

Key Facts for Investor Verification

• Cash Runway: Verify the accuracy of the management estimate that current liquidity ($902.9 million) supports operations through the second half of 2028, given the high burn rate ($255.8 million net loss in 2025).
• Clinical Data Validation: Confirm the statistical significance and clinical relevance of the APEX Phase 2 Part A results for zumilokibart, specifically the EASI-75 and EASI-90 endpoints compared to placebo and standard of care.
• Manufacturing Agreements: Review the terms of the Master Services Agreement with Samsung Biologics and the Cell Line License Agreement with WuXi Biologics, specifically regarding termination fees, exit fees, and potential supply chain disruptions related to foreign manufacturers.
• Related Party Transactions: Examine the ongoing financial relationship with Paragon Therapeutics, including milestone payments and royalty obligations, as Paragon is considered a related party.
• Patent Expiration: Verify the expected expiration dates of key patent families (ranging from 2043 to 2046) to assess the potential exclusivity period relative to the projected 2029 launch date.